CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Cyclerion Therapeutics, Inc. - CYCN CFD

3.4128
4.21%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0444
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024262 %
Charges from full value of position ($-4.61)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00204 %
Charges from full value of position ($0.39)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00204%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 3.5628
Open 3.4428
1-Year Change 31.84%
Day's Range 3.1028 - 3.4428
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 13, 2024 3.4128 -0.0300 -0.87% 3.4428 3.4428 3.0928
Dec 12, 2024 3.5628 0.0600 1.71% 3.5028 3.6928 3.4428
Dec 11, 2024 3.6828 -0.6100 -14.21% 4.2928 4.3728 3.6128
Dec 10, 2024 4.1528 -0.1400 -3.26% 4.2928 5.1728 4.0528
Dec 9, 2024 4.0428 0.3500 9.48% 3.6928 4.8628 3.5928
Dec 6, 2024 3.6028 -1.6300 -31.15% 5.2328 5.4428 3.2528
Dec 5, 2024 5.2828 0.6200 13.30% 4.6628 5.6128 4.5228
Dec 4, 2024 6.0728 0.9700 19.01% 5.1028 9.3928 4.6428
Dec 3, 2024 1.5928 -0.5500 -25.67% 2.1428 2.2028 1.5228
Dec 2, 2024 2.3328 0.1800 8.36% 2.1528 2.3628 2.0928
Nov 29, 2024 2.2028 0.0900 4.26% 2.1128 2.3028 2.0228
Nov 27, 2024 2.1128 -0.0300 -1.40% 2.1428 2.3128 1.7128
Nov 26, 2024 1.3528 -0.0400 -2.87% 1.3928 1.4028 1.2828
Nov 25, 2024 1.4428 -0.0500 -3.35% 1.4928 1.5328 1.4228
Nov 22, 2024 1.4028 -0.0100 -0.71% 1.4128 1.4828 1.2528
Nov 21, 2024 1.5128 -0.3200 -17.46% 1.8328 1.9528 1.4228
Nov 20, 2024 2.0428 0.2800 15.88% 1.7628 2.2528 1.7628
Nov 19, 2024 1.7528 -0.3600 -17.04% 2.1128 2.1928 1.7128
Nov 18, 2024 2.0828 -0.1200 -5.45% 2.2028 2.5028 1.9928
Nov 15, 2024 2.5228 0.7800 44.76% 1.7428 2.9328 1.7028

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cyclerion Therapeutics, Inc. Company profile

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cyclerion Therapeutics Inc revenues increased 72% to $3.9M. Net loss decreased 34% to $51.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research & Development - Balancing value decrease of 32% to $33.7M (expense), General & Administrative - Balancing decrease of 27% to $15M (expense).

Industry: Biotechnology & Medical Research (NEC)

301 Binney Street
CAMBRIDGE
MASSACHUSETTS 02142
US

People also watch

US100

21,741.60 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0020%
Overnight fee time 22:00 (UTC)
Spread 7.0

ETH/USD

3,848.12 Price
-1.500% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.39 Price
-2.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01191

Gold

2,648.80 Price
-1.210% 1D Chg, %
Long position overnight fee -0.0125%
Short position overnight fee 0.0043%
Overnight fee time 22:00 (UTC)
Spread 0.60

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading